Compare First Solar, Inc. (FSLR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs TG Therapeutics Inc — how do they compare? First Solar, Inc. trades at $178.43 (market cap $19.22B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: First Solar, Inc. is far larger — about 2.4× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, First Solar, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and TG Therapeutics Inc for 16 Days on average.
| FSLR | TGTX | |
|---|---|---|
Market Cap | $19.22B | $8.16B |
Volume | 2,067,793 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $318.30 | $59.06 |
52-Week Low | $172.11 | $26.94 |
Typical Hold Time | 76 Days | 16 Days |
Enterprise Value | $17.69B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $178.36, down 0.98% with bearish technical signals despite strong fundamentals. The stock shows robust revenue growth from $2.6B in 2022 to $5.2B in 2025, with net income margins expanding to 32.47%. Recent patent litigation against JA Solar and increased put option activity reflect mixed sentiment. Technical indicators show resistance at $182 and support at $175, with moving averages signaling bearish momentum.
FSLR presents a value opportunity with attractive valuation ratios (P/E 11.03, P/S 3.58) and analyst consensus price target of $267.59 (50% upside). Risks include sector-wide pressure from high borrowing costs and political uncertainty. Strong cash flow generation ($2.06B operating cash flow) and consistent earnings beats support long-term growth prospects despite near-term technical weakness.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
